This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Systemic Lupus Erythematosus전신홍반루푸스 (전신홍반 Lupus)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M32.1 (systemic lupus erythematosus with organ or system involvement) | Special Copayment Reduction: V136 (rare disease)
B. SynonymsSystemic lupus erythematosus with organ or system involvement | Systemic lupus erythematosus with endocarditis (I39.8*) | Libman–Sacks disease (I39.0*) | Lupus pericarditis (I32.8*) | Systemic lupus erythematosus with lung involvement (J99.1+) | Systemic lupus erythematosus with glomerular disease (N08.5*) | Systemic lupus erythematosus with renal tubulo-interstitial disease (N16.4*) | Systemic lupus erythematosus with renal involvement (N08.5*, N16.4*) | Encephalitis in systemic lupus erythematosus (G05.8*) | Myopathy in systemic lupus erythematosus (G73.7*) | Cerebral arteritis in systemic lupus erythematosus (I68.2*)
C. Adult onsetVery high likelihood of first presenting in adulthood — systemic lupus erythematosus has its highest incidence in women of childbearing age, 15–45 years, and about 65–75% of diagnoses are made in adulthood (mainly in the 20s–40s). First onset in adulthood is markedly more common than onset in childhood and adolescence (about 15–20%), and even after age 50, first-onset cases are reported with a changing pattern of onset owing to decreased estrogen after menopause. The female:male ratio is about 9:1, and the ratio is similar in adult first-onset patients.
1. HistoryDescriptions of skin lesions in medical literature from BC → 1851 Cazenave names it "lupus erythematosus" → 1895 Osler confirms systemic involvement → 1948 discovery of the LE cell → 1957 introduction of the antinuclear antibody (ANA) test → 1971 establishment of the ACR classification criteria → 1982 and 1997 revisions of the criteria → 2012 SLICC and 2019 EULAR/ACR new classification criteria established.
2. CausesA multifactorial autoimmune disease. Genetic predisposition (HLA-DR2/DR3, C4 deficiency, IRF5 and STAT4 polymorphisms), environmental factors (ultraviolet light, Epstein-Barr virus, smoking), hormones (female predominance related to estrogen) and epigenetic dysregulation are involved in combination, causing loss of immune tolerance to self-antigens.
3. GeneticsPolygenic. HLA-DR2 (DRB1*1501), HLA-DR3 (DRB1*0301) and C4A deficiency are the main genetic risk factors. GWAS has identified more than 100 susceptibility genes including IRF5, STAT4, BLK, PTPN22, ITGAM and TNFAIP3. Concordance in identical twins about 24–57%. X chromosome–linked susceptibility contributes to female-predominant onset.
4. General epidemiologyWorldwide prevalence about 20–150 per 100,000, incidence 1–10 per 100,000 per year. Prevalence in Korea about 20–30 per 100,000, with about 25,000 registered patients estimated. Female:male = about 9:1. Peak onset at 15–45 years. Higher prevalence and a tendency toward severity in Asian and African-descent populations.
5. PathophysiologyDefective clearance of nuclear antigens after cell death → exposure of self-antigens → activation of plasmacytoid dendritic cells (pDC) and overproduction of type I interferon → activation of autoreactive T and B cells → production of various autoantibodies such as anti-dsDNA, anti-Sm and antiphospholipid antibodies → immune complex deposition → tissue damage (especially renal glomeruli, skin, joints and blood vessels).
6. SymptomsWidespread multi-organ symptoms: fatigue and fever (systemic), arthralgia and arthritis (musculoskeletal), butterfly-shaped erythema, photosensitivity and alopecia areata (skin), pleurisy and pneumonitis (chest), pericarditis and endocarditis (heart), proteinuria, hematuria and kidney failure (kidney), headache, seizures and psychosis (nervous system), stomatitis, Raynaud phenomenon, cytopenias.
7. SignsButterfly rash, discoid lesions, oral ulcers, alopecia, arthritis (nondeforming), pleural and pericardial friction rub, renal abnormalities (proteinuria, hematuria), cytopenias (anemia, leukopenia, thrombocytopenia), positive ANA/anti-dsDNA/anti-Sm antibodies, decreased complement (C3, C4), positive antiphospholipid antibodies.
8. ScreeningGeneral population screening is not recommended. When clinically suspected: ANA (indirect immunofluorescence, HEp-2 cell substrate, positive at ≥1:80). If ANA is positive, check anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB, antiphospholipid antibodies and complement (C3, C4). Clinical attention is required when multiple autoantibodies are detected in first-degree relatives.
9. Diagnosis2019 EULAR/ACR classification criteria (entry criterion ANA ≥1:80 + weighted score ≥10 points). Clinical criteria (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) + immunologic criteria (antinuclear antibody, anti-dsDNA, anti-Sm, complement, antiphospholipid antibodies). Renal biopsy is essential for classification of lupus nephritis (ISN/RPS classification) and treatment decisions.
10. TreatmentHydroxychloroquine (HCQ, baseline treatment), NSAIDs (mild symptoms), corticosteroids (acute phase), immunosuppressants (azathioprine, mycophenolate, cyclophosphamide), belimumab (BLyS-inhibiting monoclonal antibody), anifrolumab (type I IFN receptor inhibitor). Lupus nephritis class III/IV: MMF or low-dose CTX + steroids. Antiphospholipid syndrome: anticoagulation therapy.
11. Prognosis5-year survival about 95%, 10-year about 90% (in developed countries). Main causes of death: infection (related to immunosuppression), cardiovascular disease (chronic inflammation, steroids), progression of lupus nephritis. Early treatment and long-term HCQ use improve long-term prognosis. Positive antiphospholipid antibodies, renal involvement and neuropsychiatric lupus are poor prognostic factors.
12. PreventionSun protection (daily sunscreen of SPF ≥30, UV-protective clothing), no discontinuation of HCQ, infection prevention (vaccination excluding live vaccines, hand hygiene), smoking cessation, cardiovascular risk management (control of blood pressure, lipids and blood glucose), avoidance of drugs that cause drug-induced lupus (hydralazine, procainamide, etc.), regular follow-up.
13. ReferencesAringer M et al. 2019 EULAR/ACR classification criteria for SLE. Arthritis Rheumatol. 2019 … and 9 other papers

1. History

The history of the disease name systemic lupus erythematosus (SLE) goes back to the mid-19th century, but the first medical descriptions of the skin lesions existed much earlier. Syndromes accompanied by erythematous facial lesions have been recorded since the Middle Ages, and the word "lupus" itself means "wolf" in Latin and is known to derive from the resemblance of the characteristic butterfly-shaped facial erythema to a wolf bite. Some medical-historical reviews mention that similar skin lesions were described in the Hippocratic medical literature, but a connection with SLE in the modern sense becomes possible only after the 19th century.

The beginning of modern dermatological description was in 1851, when the French dermatologist Pierre Louis Alphée Cazenave used the term "lupus erythematosus." Cazenave described erythematous discoid lesions as the main finding, and at the time the disease was understood as confined to the skin. In 1872 the Austrian dermatologist Moritz Kaposi described that the disease can be accompanied by systemic symptoms and that two types exist, discoid and disseminated, offering the first insight into its systemic nature. In 1895 the Canadian-born American physician William Osler described in detail the accompaniment of skin lesions by multi-organ involvement such as arthritis, pleurisy, kidney involvement and brain symptoms, contributing to establishing the concept of lupus as a systemic disease.

In the 20th century, understanding of SLE advanced rapidly. In 1948 Malcolm Hargraves discovered the characteristic "LE cell (lupus erythematosus cell)" in the bone marrow of lupus patients, which results from neutrophils engulfing nuclear material opsonized by antinuclear antibodies (ANA). This discovery was an important milestone, first suggesting the autoimmune nature of SLE. In 1957 George Friou developed a technique for detecting antinuclear antibodies (ANA) using indirect immunofluorescence (IIF), bringing a revolutionary change to clinical diagnosis. With the introduction of the ANA test, many patients who had previously been diagnosed ambiguously could be definitively diagnosed with SLE.

In 1971 the American College of Rheumatology (ACR, then ARA) published the first official classification criteria (11 items) for the systematic diagnosis of SLE, and revisions were made twice, in 1982 and 1997. These criteria contributed greatly to the standardization of clinical research, but the limitation of not adequately capturing early or atypical SLE was pointed out. In 2012 the Systemic Lupus International Collaborating Clinics (SLICC) group published new classification criteria that improved clinical practicality, for example by allowing classification on the basis of biopsy-confirmed lupus nephritis alone. In 2019 the European Alliance of Associations for Rheumatology (EULAR) and the ACR jointly published new classification criteria, setting ANA positivity ≥1:80 as the entry criterion and introducing a weighted scoring system with 7 clinical domains and 3 immunologic domains, improving specificity and sensitivity in a balanced way.

In the history of treatment, hydroxychloroquine (HCQ), an antimalarial drug, was known from the 1950s to be effective for skin and joint symptoms, and decades of clinical experience subsequently confirmed its effect in reducing long-term morbidity and mortality, so it is now established as the baseline treatment of SLE. Corticosteroids became the mainstay of SLE treatment after they were first used in rheumatoid arthritis in 1948, but as complications of long-term use (diabetes, osteoporosis, cardiovascular disease, infection) came to be recognized as a serious problem, steroid-sparing strategies are being emphasized. In 2011 belimumab (a monoclonal antibody inhibiting BLyS/BAFF) received FDA approval as the first SLE-specific biologic, and with the additional approval of anifrolumab (an antibody blocking the type I interferon receptor) in 2021, a new era of targeted therapy opened. In Korea as well, since the 2000s access to biologics has improved and National Health Insurance coverage has expanded, so treatment access and prognosis of SLE patients have steadily improved.


2. Causes

Systemic lupus erythematosus is a multifactorial autoimmune disease in which genetic predisposition, environmental factors, hormonal influences and epigenetic dysregulation interact in a complex way, resulting in loss of immune tolerance to self-antigens. It cannot be explained by a single cause, and it is understood that when multiple risk factors accumulate, a threshold is crossed and an autoimmune response is triggered.

Genetic predisposition: The heritability of SLE is confirmed by a concordance of about 24–57% in identical twins (about 2–5% in fraternal twins). The strongest genetic risk factor is the major histocompatibility complex (MHC) class II molecules, and the HLA-DR2 (DRB1*1501) and HLA-DR3 (DRB1*0301) genotypes in particular are strongly associated with the production of anti-Ro/SSA and anti-La/SSB antibodies and with SLE risk. Deficiencies of complement components, especially C4A (SLE risk increased more than 17-fold in complete deficiency) and C1q, are also important genetic risk factors. This leads to reduced complement-mediated clearance of immune complexes and defective clearance of apoptotic debris. Since the 2010s, genome-wide association studies (GWAS) have identified more than 100 susceptibility gene loci including IRF5, STAT4, BLK, PTPN22, ITGAM, TNFAIP3 (A20) and TNIP1, which are involved in various immune pathways such as interferon signaling, B-cell and T-cell activation thresholds and immune complex processing.

Environmental factors: Ultraviolet light (UV-B) is the best-known environmental trigger in SLE; it promotes death of skin keratinocytes and translocates nuclear antigens (especially Ro/SSA and La/SSB) to the cell surface, inducing autoantibody production. Clinically, worsening of skin lesions and flares of systemic symptoms after UV exposure are commonly observed. Epstein-Barr virus (EBV) infection is strongly suspected as an environmental trigger for the development of SLE; an excessive antibody response to EBV antigens is observed in SLE patients, and molecular mimicry between EBV proteins and autoantigens (especially the Sm antigen) has been proposed. Smoking is associated in particular with production of anti-dsDNA antibodies and worsening of skin lesions. Occupational exposures such as silica and organic solvents are also reported as risk factors. Drug-induced lupus can be caused by some drugs such as hydralazine, procainamide, minocycline, isoniazid and anti-TNF agents, and symptoms usually improve when the causative drug is stopped.

Hormonal factors: The marked female predominance of SLE (female:male = about 9:1) suggests an important role of sex hormones. Estrogen promotes B-cell and T-cell activation and strengthens anti-apoptotic effects, which may help the survival of autoreactive lymphocytes. There are also observations that elevated estrogen during pregnancy, use of oral contraceptives and estrogen replacement therapy are associated with the risk of SLE flares. In contrast, androgens are thought to have immunosuppressive effects. Prolactin is also proposed to be involved in the pathogenesis of lupus.

Epigenetic factors: Abnormal DNA methylation, histone modification and dysregulation of noncoding RNA (miRNA) are being shown to contribute to the development of SLE. In particular, global DNA hypomethylation is observed in CD4+ T cells and CD19+ B cells, leading to abnormal expression of immune genes and increased autoreactivity. The "environment–epigenetics–SLE" link, in which environmental exposure affects immune function through epigenetic changes, is currently being actively studied.


3. Genetics

Systemic lupus erythematosus is a disease with a complex polygenic mode of inheritance, in which onset is determined not by a single gene variant but by multiple susceptibility gene variants interacting with environmental factors. Genetic research on SLE can be broadly divided into ① single-gene deficiency (monogenic lupus), ② polygenic susceptibility (polygenic lupus) and ③ nongenetic inheritance (epigenetic) domains.

Single-gene deficiency (monogenic lupus): Although rare, complete deficiency or loss-of-function variants of a specific single gene sometimes cause a lupus-like phenotype at a young age. The most representative is complete deficiency of the complement component C1q, with about 90 cases reported worldwide, and lupus or a lupus-like disease develops in about 93% of those affected. C2 deficiency and complete C4 deficiency are also associated with increased SLE risk. C1q is essential for opsonization and clearance of apoptotic debris, so when it is deficient, nuclear antigens remain continuously exposed and trigger an autoimmune response. DNase I and DNase III (TREX1) deficiency also cause a lupus-like phenotype through accumulation of DNA debris. Recently, monogenic immune dysregulation such as STING1 (stimulator of interferon genes signaling) and ADA2 deficiency has also been reported to be associated with lupus-like syndromes.

Polygenic susceptibility genes: The main susceptibility genes identified through genome-wide association studies (GWAS) and meta-analyses are classified into the following functional categories. ① Interferon signaling pathway: IRF5 (interferon regulatory factor 5), IRF7, STAT4, TYK2 and IFIH1 (MDA5) contribute to overproduction of type I interferon and increased responsiveness. An "interferon signature" is observed in about 50–70% of SLE patients and is associated with disease activity and organ involvement. ② Regulation of B- and T-cell activation: BLK (B lymphocyte kinase), LYN, PTPN22 (protein tyrosine phosphatase non-receptor type 22), CD247 (TCR ζ chain) and IKBKE regulate the lymphocyte signaling threshold. ③ Immune complex processing and phagocytosis: ITGAM (CR3, CD11b), FCGR2A (FcγRIIA) and FCGR3A/B (FcγRIII) are involved in binding and clearance of immune complexes, and variants promote tissue deposition of immune complexes. ④ Regulation of NF-κB and autophagy: TNFAIP3 (A20), TNIP1 and UBE2L3 regulate NF-κB signaling and contribute to excessive inflammatory responses.

Clinical significance of HLA associations: HLA-DR2 and HLA-DR3 are each associated with an approximately 2- to 3-fold increase in SLE risk; HLA-DR2 is associated with anti-dsDNA antibodies, and HLA-DR3 especially with production of anti-Ro/SSA, anti-La/SSB and anti-Sm antibodies. HLA-DQ genotypes are also known to be associated with specific autoantibody profiles and the risk of renal involvement.

X chromosome–related genetics and female predominance: Multiple immune-related genes located on the X chromosome (TLR7, FOXP3, MECP2, etc.) are understood to contribute to the female predominance of SLE. When skewed X-inactivation occurs in women, diploid expression of certain immune genes may occur and increase autoimmune risk. TLR7 copy number variation is a rare genetic factor that increases SLE susceptibility, and it explains the excessive immune response to single-stranded RNA (ssRNA).

Epigenetics: Extensive global DNA hypomethylation is observed in CD4+ T cells, CD19+ B cells and monocytes of SLE patients, leading to overexpression of costimulatory molecules such as CD11a, CD70 and CD40L and increasing T-cell autoreactivity. Histone deacetylation (HDAC) and methylation abnormalities and dysregulation of miRNA-21, miRNA-146a and miRNA-155 are also associated with the pathogenesis of SLE.


4. General epidemiology

Systemic lupus erythematosus is a chronic autoimmune disease occurring worldwide, with considerable differences in prevalence and severity according to race, ethnicity and geographic characteristics. Overall, incidence is markedly higher in women, especially women of childbearing age, and people of color tend to have a higher incidence and a more severe course than white people.

Global epidemiology: The worldwide prevalence of SLE is reported to vary from about 20 to 150 per 100,000 depending on study method, diagnostic criteria and region. The annual incidence is about 1–10 per 100,000 per year. A prevalence of about 20–40 per 100,000 is reported in the white population of North America and Northern Europe, and 50–100 per 100,000 or more in Asian and African-descent populations. In the United States the overall prevalence of SLE is about 100–150 per 100,000, and the incidence in Black women is reported to be about 3 times higher than in white women. SLE also tends to show a severe course (especially lupus nephritis) more often in African Caribbean, Hispanic and Asian populations. It is estimated that there are more than 5 million patients worldwide.

Sex and age distribution: The female:male ratio of SLE reaches about 9:1 in the childbearing age group, and the ratio is lower in children (5:1) and the elderly (2:1). The highest incidence occurs in women aged 15–44 years, which is related to the immunoregulatory role of estrogen. SLE occurring in men tends to have a more severe course than in women, and there are also reports that lupus nephritis is more frequent and the prognosis worse. Pediatric SLE is characterized by more severe organ involvement at diagnosis and a more aggressive course.

Epidemiology in Korea: In Korea, based on Health Insurance Review & Assessment Service (HIRA) data and the Korea National Health and Nutrition Examination Survey, the prevalence of SLE is estimated at about 20–30 per 100,000, and the number of registered patients is estimated at around 25,000 as of the 2020s. About 87–90% of SLE patients in Korea are women, and the mean age at diagnosis is about 30–35 years. According to analysis of the Korean Registry of Lupus Erythematosus and Autoimmune diseases (KRELA), lupus nephritis is reported to occur in about 40–50% of SLE patients in Korea, a higher proportion than in Western white patients (about 25–30%). In Korea, SLE is registered and managed as a Special Copayment Reduction (V136) rare disease, and medical cost reduction benefits are provided to registered patients.

Trends in morbidity and mortality: With advances in modern treatment, the 5-year survival rate of SLE patients has improved greatly, from about 50% in the 1950s to about 95% at present. However, in the long term the morbidity from cardiovascular disease (coronary artery disease, cerebrovascular disease), infection, chronic kidney failure, osteoporosis and malignancy is markedly higher than in the general population, which is attributable to the chronic inflammation of the disease itself and the long-term adverse effects of immunosuppressive treatment including steroids. The prognosis is particularly poor in cases reaching end-stage kidney failure from lupus nephritis and in cases developing thrombosis from antiphospholipid syndrome.


5. Pathophysiology

The pathogenesis of systemic lupus erythematosus centers on loss of immune tolerance to self-antigens, in which a series of processes—defective clearance of apoptotic debris, overproduction of type I interferon, activation of autoreactive B and T cells, production of various autoantibodies, and immune complex formation and tissue deposition—operate in combination.

Defective clearance of apoptotic debris and exposure of nuclear antigens: Under normal conditions, debris produced by apoptosis (apoptotic bodies) is rapidly removed by macrophages and dendritic cells. In SLE this clearance process is defective, so nucleic acids (dsDNA, ssRNA), nucleoproteins (Ro/SSA, La/SSB, Sm, RNP) and phospholipids (phosphatidylserine) remain continuously exposed outside the cell. C1q deficiency, reduced DNase I and TREX1 function, and impaired macrophage phagocytosis contribute to this defect. The exposed nuclear antigens stimulate Toll-like receptors (TLR7, TLR9) and activate plasmacytoid dendritic cells (pDC).

Overproduction of type I interferon (interferon signature): When pDCs are activated by nucleic acid–autoantibody immune complexes, they secrete large amounts of type I interferon (IFN-α, IFN-β). This type I IFN exerts pleiotropic effects that contribute to dendritic cell maturation, monocyte activation, increased autoreactivity of B and T cells and inhibition of clearance of apoptotic cells. Clinical and basic studies continue to report that the higher the type I IFN activity in the serum of SLE patients and the expression of IFN-stimulated genes in blood cells (interferon signature), the greater the association with disease activity, lupus nephritis and neuropsychiatric lupus. Anifrolumab is a drug targeting this mechanism.

Activation of autoreactive B and T cells and production of autoantibodies: Type I IFN and various costimulatory signals activate autoreactive B cells and CD4+ helper T cells (especially Tfh, follicular helper T cells). In this process BAFF (BLyS, B-cell activating factor) and APRIL promote B-cell survival and proliferation. Activated plasma cells secrete various autoantibodies, and the clinically most important of these are anti-double-stranded DNA (anti-dsDNA) antibodies and anti-Sm antibodies. Anti-dsDNA antibodies play a key role in diagnosis and monitoring owing to high SLE specificity (about 95%) and the ability to reflect disease activity (especially lupus nephritis). Antiphospholipid antibodies (anticardiolipin, anti-β2-glycoprotein I, lupus anticoagulant) are important autoantibodies that cause thrombosis and pregnancy complications (antiphospholipid syndrome).

Immune complex formation and tissue damage: Immune complexes formed by autoantibodies binding to nuclear antigens, DNA and phospholipids are not cleared in the circulation and are deposited in the renal glomerular basement membrane, the dermal–epidermal junction of the skin, vessel walls, synovial membranes and elsewhere. Immune complex deposition triggers a cascade of complement activation (classical pathway) → C3a and C5a generation → influx of neutrophils and monocytes → release of inflammatory cytokines → tissue damage. In the kidney this process manifests as glomerulonephritis (lupus nephritis), and in blood vessels as vasculitis. On fluorescence microscopy of a renal biopsy, "full-house" deposition of IgG, IgA, IgM, C3 and C1q is the pathological hallmark of lupus nephritis.

Mechanisms of neuropsychiatric lupus: Central nervous system involvement involves multiple mechanisms including autoantibodies (anti-NMDAR, antiphospholipid, anti-ribosomal P), cytokines (IL-6, TNF-α, type B IFN), immune complex–mediated vasculitis and thromboembolism. Reduced blood–brain barrier (BBB) function allows autoantibodies and inflammatory mediators to enter the CNS.


6. Symptoms

Systemic lupus erythematosus is a chronic multisystem autoimmune disease that can involve almost any organ, and the range and severity of symptoms vary greatly from patient to patient. Symptoms can be broadly divided into constitutional symptoms, skin and mucosal symptoms, musculoskeletal symptoms, cardiopulmonary symptoms, renal symptoms, neuropsychiatric symptoms and hematologic symptoms, which occur alone or in combination.

Constitutional symptoms: Chronic fatigue is the most common symptom, reported in about 80–90% of patients; it does not always correspond to disease activity and is associated in a complex way with depression, anxiety, pain and sleep disorders. Fever is common during disease exacerbation, and distinguishing it from infection is clinically very important. Weight loss, lymphadenopathy and decreased appetite may also accompany it.

Skin and mucosal symptoms: The skin is one of the organs with the most varied manifestations in SLE. The most characteristic finding of acute cutaneous lupus erythematosus (ACLE) is the malar rash (butterfly rash), an erythematous eruption in a butterfly shape across both cheeks and the bridge of the nose that spares the nasolabial fold. This erythema worsens after ultraviolet exposure and is observed in about 50% of patients. Subacute cutaneous lupus (SCLE) shows annular or papulosquamous lesions mainly in photoexposed areas and is strongly associated with anti-Ro/SSA antibodies. Discoid lupus erythematosus (DLE) begins as erythematous discoid lesions and progresses to central atrophy, hyperpigmentation/depigmentation and follicular plugging, occurs mainly on the scalp and face, and can cause permanent alopecia. Photosensitivity occurs in about 60–70% and presents as worsening of skin lesions or of systemic symptoms after ultraviolet exposure. Oral ulcers are usually painless, occur frequently on the palate and are a marker of disease activity. Raynaud's phenomenon is observed in about 20–30% of SLE patients and shows the typical finding of fingers turning white–blue–red due to vasospasm.

Musculoskeletal symptoms: Arthralgia or arthritis is the most common symptom, experienced by about 90% of SLE patients. It is characterized by non-deforming, non-erosive symmetric polyarthritis, mainly affecting the joints of the hands, wrists and knees. Rarely, reversible subluxation called Jaccoud's arthropathy occurs. Myalgia, muscle weakness and lupus myositis may also occur. Avascular necrosis (AVN) is associated with long-term corticosteroid use and antiphospholipid antibodies, and the femoral head is most commonly involved.

Cardiopulmonary symptoms: Pleuritis occurs in about 30–40% of SLE patients and is characterized by chest pain that worsens with breathing. Pericarditis also occurs in about 20–30%. Libman-Sacks endocarditis, a nonbacterial verrucous valve lesion (mainly on the posterior leaflet of the mitral valve), is associated with SLE and antiphospholipid syndrome. Lupus pneumonitis is accompanied by fever, cough and dyspnea, and pulmonary infiltrates appear on imaging. Pulmonary hypertension, systolic cardiomyopathy and myocarditis also occur rarely.

Renal symptoms: Lupus nephritis (LN) occurs in about 40–60% of SLE patients and is the complication with the greatest effect on long-term prognosis. In the early stage it may present only as asymptomatic proteinuria and hematuria, and as it progresses it worsens to edema, hypertension, nephrotic syndrome (daily proteinuria of 3.5 g or more) and kidney failure. Inadequately treated class III/IV (proliferative) lupus nephritis can progress to end-stage renal disease (ESRD) within 10–20 years.

Neuropsychiatric symptoms: Neuropsychiatric lupus (NPSLE) involves the central and peripheral nervous systems and presents with various symptoms such as headache (about 50%), cognitive decline, mood disorders (depression, anxiety), psychosis, seizures, stroke, peripheral neuropathy, autonomic abnormalities and acute confusional state (delirium).

Hematologic symptoms: Anemia (normochromic normocytic anemia, autoimmune hemolytic anemia), leukopenia (especially lymphopenia) and thrombocytopenia are common, and all three may occur simultaneously. In patients positive for antiphospholipid antibodies, thrombosis (venous thrombosis, arterial thrombosis, stroke) and recurrent pregnancy loss occur.


7. Signs

The physical signs of systemic lupus erythematosus vary according to the organs involved and change with disease activity and course. The following summarizes the representative clinical signs by major organ system.

Skin and mucosal signs: The malar rash is an erythematous eruption distributed symmetrically on both cheeks and is characterized by sparing of the nasolabial fold. During acute exacerbation it appears as an erythematous plaque with edema and feels slightly warm on palpation. On oral mucosal examination, painless ulcers (especially of the hard palate, soft palate and buccal mucosa) are observed. On scalp examination, diffuse or patchy alopecia is identified, and alopecia due to discoid lesions is scarring and may be permanent. Cutaneous vasculitis findings may include macular erythema of the fingertips and toe tips, mesh-like skin color change (livedo reticularis) and nailfold capillary abnormalities.

Joint signs: Tenderness and mild swelling are observed on palpation of the finger joints (MCP, PIP), wrists and knees on both sides, and in Jaccoud's arthropathy joint subluxation (especially ulnar deviation of the MCP joints) is observed. In most cases no erosion or joint damage is seen on radiographs, which distinguishes it from rheumatoid arthritis.

Chest signs: A pleural friction rub may be heard on auscultation in pleuritis, and when effusion increases, breath sounds decrease and dullness is found on percussion. With pericardial effusion, the heart sounds are distant (muffled heart sounds), and a pericardial friction rub may be heard. Valve dysfunction due to Libman-Sacks endocarditis may appear as a systolic murmur (mitral regurgitation).

Renal signs: During the active phase of lupus nephritis, elevated blood pressure, pitting edema of the face and lower limbs, and ascites may appear. In nephrotic syndrome, marked facial edema, generalized edema and hypoalbuminemia are observed. On urinalysis, foamy proteinuria and hematuria are seen with the naked eye or are positive on dipstick testing.

Neurological signs: Focal neurological deficits (hemiplegia, aphasia, etc.) may appear owing to stroke or vasculitis. Seizures and signs of meningeal irritation (neck stiffness, Kernig's sign) appear in lupus encephalitis or meningitis. In peripheral neuropathy, sensory abnormalities, muscle weakness and decreased deep tendon reflexes are observed.

Major laboratory findings: Positive ANA (≥1:80, sensitivity above 95%), positive anti-dsDNA antibody (specificity above 95%), positive anti-Sm antibody (specificity >99%). Decreased complement C3 and C4 (reflecting consumption by immune complexes). Cytopenias (leukopenia < 4,000/μL, lymphopenia < 1,000/μL, thrombocytopenia < 100,000/μL). Positive direct Coombs' test (autoimmune hemolytic anemia). Urinalysis: proteinuria (> 500 mg/24h or protein/creatinine ratio > 0.5); red blood cell (RBC) casts strongly suggest class III/IV lupus nephritis. CRP is usually normal or mildly elevated (markedly elevated in bacterial infection, which helps distinguish it from an SLE flare), and ESR is elevated.


8. Screening

Screening tests for systemic lupus erythematosus in the general population are not currently recommended. Because the prevalence of SLE is low and ANA positivity is a nonspecific finding that occurs in 5–15% of the normal population, SLE cannot be diagnosed on the basis of an isolated positive ANA without symptoms. However, a systematic testing approach in patients clinically suspected of having SLE and screening counseling for first-degree relatives of already diagnosed patients are meaningful.

Initial screening test — ANA (antinuclear antibody) test: The first screening test performed when SLE is clinically suspected is the ANA test by indirect immunofluorescence (IIF) using HEp-2 cell substrate. A titer ≥1:80 is defined as positive, and sensitivity in SLE is very high at about 95–99%, so a negative result can virtually exclude the diagnosis of SLE. However, a positive result alone cannot diagnose SLE, and the next step of specific autoantibody testing is required. ANA fluorescence patterns are divided into homogeneous (associated with anti-dsDNA and antihistone), speckled (associated with anti-Sm, anti-RNP, anti-Ro/SSA and anti-La/SSB) and nucleolar, and the pattern is useful for directing testing.

Specific autoantibody panel: After a positive ANA, the following antibody panel is performed and used to determine whether SLE diagnostic criteria are met and to predict organ involvement. Anti-dsDNA antibody (anti-double-stranded DNA antibody): SLE specificity about 95%, associated with disease activity and lupus nephritis. Anti-Sm antibody: SLE specificity about 99%; sensitivity is low but a positive result carries high diagnostic weight. Anti-Ro/SSA antibody: associated with neonatal lupus, subacute cutaneous lupus and Sjögren syndrome; predicts photosensitivity. Anti-La/SSB antibody: commonly accompanies anti-Ro/SSA; risk of neonatal lupus (congenital heart block). Antiphospholipid antibodies (anticardiolipin IgG/IgM, anti-β2-GPI IgG/IgM, lupus anticoagulant): diagnosis and risk assessment of antiphospholipid syndrome (thrombosis, pregnancy loss). Antihistone antibody: especially positive in drug-induced lupus.

Complement tests: Decreased C3 and C4 complement levels reflect immune complex activation and consumption and are a marker of disease activity (especially exacerbation of lupus nephritis). The CH50 (total complement activity) test is also used as a supplement. C4 levels may have different baselines depending on the C4A/C4B gene copy number, so caution is needed in interpretation.

Urinalysis and renal function assessment: In all patients with suspected or confirmed SLE, regular urinalysis (including urine sediment), urine protein/creatinine ratio, serum creatinine and eGFR are measured. RBC casts, white blood cell casts, or proteinuria (≥500 mg/24h or protein/creatinine ratio ≥0.5) strongly suggest lupus nephritis and are indications for renal biopsy.

Blood tests: Complete blood count with differential (CBC with differential): confirm leukopenia, lymphopenia, thrombocytopenia and anemia. Direct Coombs' test: differentiate autoimmune hemolytic anemia. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP): assess inflammatory activity (CRP is markedly elevated in bacterial infection, which is useful for distinguishing it from an SLE flare). Liver function tests: assess lupus hepatitis or drug toxicity. Thyroid function tests: check for coexisting autoimmune thyroid disease.

Imaging tests: Chest X-ray or CT: evaluate pleural effusion, pulmonary infiltrates and cardiomegaly. Echocardiography: evaluate pericardial effusion, valve lesions (Libman-Sacks endocarditis) and pulmonary hypertension. Head MRI: performed when neuropsychiatric lupus is suspected. Joint ultrasound or MRI: evaluate arthritis and Jaccoud's arthropathy.


9. Diagnosis

The diagnosis of systemic lupus erythematosus is based on classification criteria that integrate clinical features, serology and histopathology. The classification criteria most widely used in clinical practice and research at present are the 2019 EULAR/ACR classification criteria, which require a positive antinuclear antibody (ANA) (≥1:80, IIF, HEp-2 substrate) as the mandatory entry criterion and classify as SLE a summed weighted score of ≥10 points across 7 clinical domains and 3 immunologic domains.

Composition of the 2019 EULAR/ACR classification criteria: The entry criterion is a positive ANA ≥1:80 (IIF or an equivalent method). The clinical domains that follow are ① constitutional domain (fever ≥38.3°C, 2 points), ② hematologic domain (leukopenia 3 points, thrombocytopenia 4 points, autoimmune hemolytic anemia 4 points), ③ neuropsychiatric domain (delirium 2 points, psychosis 3 points, seizure 5 points), ④ mucocutaneous domain (non-scarring alopecia 2 points, oral ulcers 2 points, subacute cutaneous lupus or discoid lupus 4 points, acute cutaneous lupus 6 points), ⑤ serosal domain (pleural or pericardial effusion 5 points, acute pericarditis 6 points), ⑥ musculoskeletal domain (joint involvement 6 points), and ⑦ renal domain (proteinuria 4 points, renal biopsy class II or V lupus nephritis 8 points, class III or IV lupus nephritis 10 points). The immunologic domains include ⑧ antiphospholipid antibodies (2 points), ⑨ complement proteins (low C3 or C4, 3 points; both C3 and C4 low, 4 points) and ⑩ SLE-specific antibodies (anti-dsDNA or anti-Sm, 6 points). Only the highest score in each domain is summed, and an item is not counted if the finding is better explained by another disease.

Renal biopsy (classification of lupus nephritis): Renal biopsy is essential for diagnosing lupus nephritis and determining the direction of treatment. According to the 2018 revised classification of the International Society of Nephrology/Renal Pathology Society (ISN/RPS), it is classified into 6 classes in total. Class I (minimal mesangial lupus nephritis): normal on light microscopy, immunofluorescence deposits. Class II (mesangial proliferative lupus nephritis): mild mesangial proliferation. Class III (focal lupus nephritis): subendothelial deposits and cell proliferation in less than 50% of glomeruli, divided into active (A) or chronic (C). Class IV (diffuse lupus nephritis): involvement of 50% or more of glomeruli, segmental (IV-S) or global (IV-G), active (A) or chronic (C). Class V (membranous lupus nephritis): glomerular thickening with subepithelial immune deposits. Class VI (advanced sclerosing lupus nephritis): global sclerosis of 90% or more of glomeruli. Class III/IV is the most severe form and requires immediate immunosuppressive treatment, and class V is treated when it causes nephrotic syndrome.

Differential diagnosis: SLE presents with symptoms involving various organs, so differentiation from many diseases is needed. It is important to distinguish it from rheumatoid arthritis (autoantibody pattern, joint erosion, CCP antibody), Sjögren syndrome (predominant dry mouth and dry eyes, isolated positivity of anti-Ro/SSA and anti-La/SSB), mixed connective tissue disease (MCTD, strongly positive anti-U1 RNP antibody), systemic sclerosis (skin fibrosis, anti-Scl-70 antibody), polymyositis/dermatomyositis (elevated muscle enzymes, myositis-specific antibodies), vasculitis (ANCA antibodies), infection (transient ANA positivity especially after EBV and bacterial infection), malignancy (paraneoplastic syndrome) and drug-induced lupus (positive antihistone antibody, improvement on stopping the causative drug).

Disease activity assessment tools: Standardized activity indices (SLEDAI-2K, BILAG-2004, ECLAM) are used in clinical research and practice. SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) is a weighted scoring system composed of 24 items and is widely used for acute and long-term clinical management. The SLICC/ACR Damage Index (SDI) is used to assess cumulative organ damage.


10. Treatment

The goals of treatment of systemic lupus erythematosus are suppression of disease activity, prevention of organ damage, improvement of quality of life, and minimization of infection and cardiovascular risk. Treatment is individualized according to disease severity, organs involved and activity, and consists broadly of ① baseline hydroxychloroquine treatment, ② corticosteroids, ③ non-biologic immunosuppressants and ④ biologic agents.

Hydroxychloroquine (HCQ): HCQ is recommended as baseline treatment in all SLE patients without contraindications. As an antimalarial drug, it modulates the autoimmune response by inhibiting TLR signaling and antigen presentation. Long-term HCQ use has been shown to reduce SLE mortality by about 25–30%, reduce the occurrence of lupus nephritis, prevent flares, reduce thrombosis and cardiovascular risk, and reduce pregnancy complications. The standard dose is 5 mg/kg/day or less (based on ideal body weight), and an annual eye examination is needed to prevent retinal toxicity related to cumulative dose. HCQ is safe during pregnancy, and continuation is recommended in pregnant women with SLE as well.

Corticosteroids: Used for rapid suppression of acute exacerbation (flare) or organ involvement (lupus nephritis, neuropsychiatric lupus, hemolytic anemia, etc.). Oral prednisolone is used at 5–15 mg/day for mild symptoms, 0.5 mg/kg/day for moderate and up to 1 mg/kg/day for severe disease. During induction for class III/IV lupus nephritis, high-dose oral or intravenous methylprednisolone pulse therapy (500–1,000 mg/day × 3 days) is used. To minimize the complications of long-term steroid use (cardiovascular risk, osteoporosis, diabetes, infection, adrenal suppression), the dose is tapered as quickly as possible and a steroid-sparing strategy is used. The goal is to keep the maintenance dose at prednisolone 5 mg/day or less, or to discontinue it.

Non-biologic immunosuppressants: Azathioprine (AZA) and mycophenolate mofetil (MMF) are the most widely used for steroid sparing and maintenance treatment. AZA (1.5–2.5 mg/kg/day) is an option for maintenance treatment of skin, joint and hematologic involvement and can be used in pregnant women. MMF (1.5–3 g/day) is recommended as the first choice for induction and maintenance treatment of lupus nephritis. For severe lupus nephritis or life-threatening involvement, cyclophosphamide (CTX) is used as induction treatment. The low-dose EuroLupus regimen (500 mg IV × 6 doses every 2 weeks) shows efficacy similar to the high-dose NIH regimen with lower toxicity and is preferred. Calcineurin inhibitors (tacrolimus, cyclosporine) are used selectively in membranous lupus nephritis refractory to MMF or in Asian patients. Methotrexate (MTX) may be used as an adjunct for arthritis and skin symptoms.

Biologic agents: Belimumab is a humanized monoclonal antibody targeting BLyS/BAFF (B-cell activating factor) and was the first SLE-specific biologic to receive FDA approval in 2011, after 50 years. It is given by intravenous or subcutaneous injection, and when added to standard treatment (HCQ + steroids ± immunosuppressants) it reduces flares, reduces cumulative organ damage and reduces steroid dose. An additional indication was approved for lupus nephritis (class III/IV) as well. Anifrolumab is an antibody that blocks the type I interferon receptor (IFNAR1) and was approved by the FDA in 2021 for active SLE (moderate to severe, with inadequate standard treatment). It has excellent effects on skin and joint symptoms and steroid sparing, and the effect is particularly prominent in patients positive for the interferon signature.

Treatment of antiphospholipid syndrome: When thrombosis occurs in an SLE patient positive for antiphospholipid antibodies, long-term anticoagulation (warfarin, target INR 2–3) is recommended. For primary thromboprophylaxis, low-dose aspirin and HCQ are standard. Because the TRAPS trial showed a higher rate of thrombotic recurrence with DOACs (direct oral anticoagulants) than with warfarin in antiphospholipid syndrome, DOACs are currently used with caution in APS. For management of antiphospholipid syndrome during pregnancy, combination of low-molecular-weight heparin + low-dose aspirin is standard.


11. Prognosis

The prognosis of systemic lupus erythematosus has improved markedly over the past half century. In the 1950s the 5-year survival of SLE was only about 50–60%, but in the 2020s the 5-year survival in developed countries reaches about 95% and the 10-year survival about 90%. However, SLE is still a chronic disease that causes earlier death and serious morbidity than in the general population, and prevention of long-term complications is a core task of treatment.

Major prognostic determinants: Factors associated with poor prognosis include lupus nephritis (especially class III/IV), neuropsychiatric lupus, positive antiphospholipid antibodies (risk of thrombosis and pregnancy loss), persistently low complement levels and high anti-dsDNA antibody titers, frequent flares, older age at onset, male sex, Black and Hispanic race and low socioeconomic status. In contrast, long-term continued use of HCQ, multidisciplinary management at a specialized lupus clinic, early diagnosis and treatment, and maintaining normal renal function are associated with good prognosis.

Change in causes of death: In the past, active lupus itself (kidney failure, central nervous system involvement, bleeding) was the main cause of death, but with advances in modern treatment, infection (related to immunosuppression, especially pneumonia and sepsis) and cardiovascular disease (coronary artery disease, cerebrovascular disease) have emerged as the main causes of death. The risk of coronary artery disease in SLE patients is 2 to 10 times that of the general population, and a 50-fold higher risk has been reported especially in women under 45. This is attributable to chronic systemic inflammation, steroid-induced metabolic complications (diabetes, dyslipidemia, hypertension) and direct vascular inflammation.

Long-term prognosis of lupus nephritis: In patients with class III/IV lupus nephritis, despite aggressive immunosuppressive treatment, about 10–20% progress to end-stage renal disease (ESRD) within 10–20 years. Patients reaching ESRD need hemodialysis or kidney transplantation, and after transplantation the risk of SLE recurrence is low but immunosuppression-related complications are important. Achieving complete renal remission (resolution of proteinuria, stabilization of eGFR) early is the most important prognostic factor for preserving long-term renal function.

Pregnancy prognosis: Pregnancy in SLE patients has relatively good outcomes when there is remission for 6 months or more before pregnancy, continued HCQ, stable lupus nephritis and negative antiphospholipid antibodies. In contrast, in pregnancies with active lupus, accompanying lupus nephritis or positive anti-Ro/SSA antibodies, the risks of preeclampsia, preterm birth, fetal growth restriction and neonatal lupus (including congenital heart block) increase. Careful planning before pregnancy and multidisciplinary consultation are essential.

Long-term complications: Osteoporosis and fractures (steroid-related), avascular necrosis of the femoral head, premature menopause (ovarian toxicity related to CTX), secondary diabetes, hypertension and dyslipidemia, cataract, susceptibility to infection and cognitive decline are managed as long-term complications. In SLE patients the incidence of lymphoma and cervical cancer in particular is higher than in the general population, so regular cancer surveillance is recommended.


12. Prevention

There is currently no way to completely prevent the onset of systemic lupus erythematosus itself. However, various preventive strategies are clinically recommended to reduce the risk of onset, prevent disease flares and minimize organ damage.

Primary prevention — reducing the risk of onset: In high-risk groups with genetic predisposition (first-degree relatives of SLE patients), minimizing ultraviolet exposure, smoking cessation, avoiding occupational exposure to silica and organic solvents, and managing EBV-related infection may theoretically contribute to risk reduction. When prescribing drugs that cause drug-induced lupus (hydralazine, procainamide, isoniazid, minocycline, anti-TNF agents, etc.), patients are educated to report immediately if SLE-like symptoms occur. In women with a family history in whom asymptomatic autoimmune abnormalities such as positive ANA, multiple positive autoantibodies or low complement are identified, they are carefully followed as "preclinical SLE" or "undifferentiated connective tissue disease (UCTD)," and preemptive HCQ administration can be discussed with a specialist.

Ultraviolet protection: In diagnosed SLE patients, ultraviolet light is the most important flare trigger, so sun protection is the key lifestyle preventive measure. A broad-spectrum sunscreen of SPF 50 or higher that blocks both UVA and UVB is reapplied every 2–3 hours daily when exposed to sunlight. Long-wavelength UVA can also worsen SLE, so caution is also needed regarding indoor exposure through window glass. Wearing photoprotective clothing (UPF 50+ material), a wide-brimmed hat and UV-blocking glasses is recommended. Patients are educated to use shade when outdoors and to refrain from going out between 10 a.m. and 2 p.m., when ultraviolet light is strongest.

Continued HCQ use: Arbitrarily stopping HCQ markedly increases the risk of flares, so patients are actively educated not to stop HCQ even when asymptomatic or in remission. HCQ is recommended to be continued during pregnancy as well, and retinal toxicity is detected early through annual eye examinations.

Infection prevention: SLE patients on immunosuppressive treatment have a high risk of infection. Vaccinations (annual influenza vaccine, pneumococcal vaccine, hepatitis B vaccine, cervical cancer vaccine) are kept up to date, but live vaccines (varicella, MMR, yellow fever, BCG, etc.) are contraindicated during immunosuppression. Hand hygiene education, screening for latent tuberculosis infection (caution about drug-induced lupus with isoniazid preventive therapy) and prevention of opportunistic infection (TMP-SMX for Pneumocystis pneumonia prophylaxis) are important.

Cardiovascular risk management: Cardiovascular disease is a main cause of morbidity and mortality in SLE patients, so blood pressure, blood glucose and lipids are optimally managed and smoking cessation is maintained. The steroid dose is minimized, exercise and a healthy diet are recommended, and osteoporosis is also prevented through vitamin D and calcium supplementation. Aspirin (75–100 mg/day) is recommended for primary thromboprophylaxis in patients positive for antiphospholipid antibodies.

Regular follow-up: At a lupus specialty clinic, blood and urine tests, the activity index (SLEDAI-2K) and organ damage assessment are performed regularly (every 3–6 months in remission, every 1–3 months with active disease). In lupus nephritis patients, urine protein/creatinine ratio, serum creatinine, complement and anti-dsDNA antibody are monitored regularly. Education so that patients themselves recognize early warning signs of worsening and report them to the medical team contributes to early treatment of flares and prevention of organ damage.


13. References

  1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. DOI: 10.1002/art.40930. PMID: 31385462.

  2. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089. PMID: 30926722.

  3. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus (TULIP-2). N Engl J Med. 2020;382(3):211-221. DOI: 10.1056/NEJMoa1912196. PMID: 31851795.

  4. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. DOI: 10.1056/NEJMoa2001180. PMID: 32937045.

  5. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1). Lancet. 2021;397(10289):2070-2080. DOI: 10.1016/S0140-6736(21)00578-X. PMID: 33971155.

  6. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. DOI: 10.1056/NEJMra1100359. PMID: 22129255.

  7. Kim WU, Min JK, Lee SH, et al. Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol. 1999;17(5):539-545. PMID: 10544835.

  8. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473. PMID: 22553077.

  9. Yap DYH, Tang CSO, Ma MKM, et al. Longterm data on tacrolimus treatment in lupus nephritis. J Rheumatol. 2014;41(10):2036-2042. DOI: 10.3899/jrheum.131285. PMID: 25128511.

  10. Urowitz MB, Gladman DD, Ibanez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012;64(1):132-137. DOI: 10.1002/acr.20648. PMID: 21972104.